Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hawkins, M.
Right arrow Articles by Shamoon, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hawkins, M.
Right arrow Articles by Shamoon, H.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 51:2179-2189, 2002
© 2002 by the American Diabetes Association, Inc.

Glycemic Control Determines Hepatic and Peripheral Glucose Effectiveness in Type 2 Diabetic Subjects

Meredith Hawkins, Ilan Gabriely, Robert Wozniak, Kalpana Reddy, Luciano Rossetti, and Harry Shamoon

Division of Endocrinology and Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, New York

Glucose effectiveness is impaired in type 2 diabetes. We hypothesize that chronic hyperglycemia and hyperlipidemia contribute importantly to this defect. To test this hypothesis, we compared the effect of acute hyperglycemia on glucose turnover in type 2 diabetic subjects in good control (GC) (n = 14, age 51.7 ± 3.7 years, BMI 28.4 ± 1.0 kg/ m2, HbA1c 5.9 ± 0.2%) and poor control (PC) (n = 10, age 50.0 ± 2.5 years, BMI 27.9 ± 1.5 kg/m2, HbA1c 9.9 ± 0.6%) with age- and weight-matched nondiabetic subjects (ND) (n = 11, age 47.0 ± 4.4 years, BMI 28.5 ± 1.0 kg/m2, HbA1c 5.1 ± 0.2%). Fixed hormonal conditions were attained by infusing somatostatin for 6 h with replacement of basal insulin, glucagon, and growth hormone. Glucose fluxes ([3-3H]glucose) were compared during euglycemic (5 mmol/l, t = 180–240 min) and hyperglycemic (Hy) (10 mmol/l, t = 300–360 min, variable glucose infusion) clamp intervals. Acute hyperglycemia suppressed hepatic glucose production (GP) by 43% and increased peripheral glucose uptake (GU) by 86% in the ND subjects. Conversely, GP failed to suppress (-7%) and GU was suboptimally increased (+34%) in response to Hy in the PC group. However, optimal glycemic control was associated with normal glucose effectiveness in GC subjects (GP -38%, GU +72%; P > 0.05 for GC vs. ND). To determine whether short-term correction of hyperglycemia and/or hyperlipidemia is sufficient to reverse the impairment in glucose effectiveness, five PC subjects were restudied after 72 h of normoglycemia (~100 mg/dl; variable insulin infusions). These subjects regained normal effectiveness of glucose to suppress GP and stimulate GU and in response to Hy (GP -47%, GU + 71%; P > 0.05 vs. baseline studies). Thus, chronic hyperglycemia and/or hyperlipidemia contribute to impaired effectiveness of glucose in regulating glucose fluxes in type 2 diabetes and hence to worsening of the overall metabolic condition. Short-term normalization of plasma glucose might break the vicious cycle of impaired glucose effectiveness in type 2 diabetes.



Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
W. Li, J. Tonelli, P. Kishore, R. Owen, E. Goodman, P. E. Scherer, and M. Hawkins
Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle
Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1301 - E1307.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
Y. Fujimoto, T. P. Torres, E. P. Donahue, and M. Shiota
Glucose Toxicity Is Responsible for the Development of Impaired Regulation of Endogenous Glucose Production and Hepatic Glucokinase in Zucker Diabetic Fatty Rats
Diabetes, September 1, 2006; 55(9): 2479 - 2490.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
P. Kishore, J. Tonelli, S. Koppaka, C. Fratila, A. Bose, D.-E. Lee, K. Reddy, and M. Hawkins
Time-Dependent Effects of Free Fatty Acids on Glucose Effectiveness in Type 2 Diabetes
Diabetes, June 1, 2006; 55(6): 1761 - 1768.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. A. Elder, R. L. Prigeon, R. P. Wadwa, L. M. Dolan, and D. A. D'Alessio
{beta}-Cell Function, Insulin Sensitivity, and Glucose Tolerance in Obese Diabetic and Nondiabetic Adolescents and Young Adults
J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 185 - 191.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
D. Aftab Guy, D. Sandoval, M. A. Richardson, D. Tate, and S. N. Davis
Effects of glycemic control on target organ responses to epinephrine in type 1 diabetes
Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E258 - E265.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
J. Shao, L. Qiao, R. C. Janssen, M. Pagliassotti, and J. E. Friedman
Chronic Hyperglycemia Enhances PEPCK Gene Expression and Hepatocellular Glucose Production Via Elevated Liver Activating Protein/Liver Inhibitory Protein Ratio
Diabetes, April 1, 2005; 54(4): 976 - 984.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
R. Basu, W. F. Schwenk, and R. A. Rizza
Both fasting glucose production and disappearance are abnormal in people with "mild" and "severe" type 2 diabetes
Am J Physiol Endocrinol Metab, July 1, 2004; 287(1): E55 - E62.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
J. Tonelli, W. Li, P. Kishore, U. B. Pajvani, E. Kwon, C. Weaver, P. E. Scherer, and M. Hawkins
Mechanisms of Early Insulin-Sensitizing Effects of Thiazolidinediones in Type 2 Diabetes
Diabetes, June 1, 2004; 53(6): 1621 - 1629.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
M. Hawkins, J. Tonelli, P. Kishore, D. Stein, E. Ragucci, A. Gitig, and K. Reddy
Contribution of Elevated Free Fatty Acid Levels to the Lack of Glucose Effectiveness in Type 2 Diabetes
Diabetes, November 1, 2003; 52(11): 2748 - 2758.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Vella, A. S. Reed, N. Charkoudian, P. Shah, R. Basu, A. Basu, M. J. Joyner, and R. A. Rizza
Glucose-induced suppression of endogenous glucose production: dynamic response to differing glucose profiles
Am J Physiol Endocrinol Metab, July 1, 2003; 285(1): E25 - E30.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2002 by the American Diabetes Association.